Ignite Creation Date:
2025-12-25 @ 4:20 AM
Ignite Modification Date:
2026-02-25 @ 12:57 AM
Study NCT ID:
NCT02332720
Status:
COMPLETED
Last Update Posted:
2019-07-30
First Post:
2015-01-06
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-01-28
Start Date Type:
ACTUAL
Primary Completion Date:
2016-09-19
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-05-03
Completion Date Type:
ACTUAL
First Submit Date:
2015-01-06
First Submit QC Date:
None
Study First Post Date:
2015-01-07
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-04-24
Results First Submit QC Date:
None
Results First Post Date:
2018-07-02
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-07-18
Last Update Post Date:
2019-07-30
Last Update Post Date Type:
ACTUAL